4-Methylmorpholine → HCID 178522506, Verbindung
Reaktionsgleichung
[N:1]1[CH:6]=[C:5]([C:7]([OH:9])=O)[CH:4]=[N:3][CH:2]=1.CN(C(ON1N=NC2C=CC=NC1=2)=[N+](C)C)C.F[P-](F)(F)(F)(F)F.CN1CCOCC1.[N:41]1([S:47]([CH2:50][CH2:51][CH2:52][O:53][C:54]2[CH:55]=[CH:56][C:57]3[C:58]4[N:59]([CH2:65][CH2:66][N:67]=4)[C:60]([NH2:64])=[N:61][C:62]=3[CH:63]=2)(=[O:49])=[O:48])[CH2:46][CH2:45][O:44][CH2:43][CH2:42]1>CN(C=O)C.CCOC(C)=O>[N:41]1([S:47]([CH2:50][CH2:51][CH2:52][O:53][C:54]2[CH:55]=[CH:56][C:57]3[C:58]4[N:59]([CH2:65][CH2:66][N:67]=4)[C:60]([NH:64][C:7]([C:5]4[CH:4]=[N:3][CH:2]=[N:1][CH:6]=4)=[O:9])=[N:61][C:62]=3[CH:63]=2)(=[O:48])=[O:49])[CH2:46][CH2:45][O:44][CH2:43][CH2:42]1Komponenten
7
Edukt 4
Produkt 1
Reagenzien, Katalysatoren, Lösungsmittel 2
Versuchsvorschrift
To pyrimidine-5-carboxylic acid (95.0 mg, 0.77 mmol) in DMF (1 ml) was added HATU (342 mg, 0.9 mmol) and 4-methylmorpholine (91 mg, 0.9 mmol). The mixture was stirred for 5 min then 8-[3-(morpholin-4-ylsulfonyl)propoxy]-2,3-dihydroimidazo[1,2-c]quinazolin-5-amine (Step 1, 250 mg, 0.64 mmol) in DMF (2 mL) was added. The resulting solution was allowed to stir at rt for 16 h. It was diluted with EtOAc and filtered rinsing with EtOAc and MeOH to give the title compound (195 mg, 61%). TLC Rf=0.68 in 10% MeOH/CH2Cl2, HPLC MS RT=1.13 min, MH+=500.4; 1H NMR (DMSO-d6) δ: 2.25 (2H, m), 3.21 (4H, m), 3.30 (2H, m), 3.67 (4H, m), 4.23 (2H, t), 4.31 (2H, t), 4.60 (2H, t), 7.25 (1H, d), 7.78 (1H, s), 8.16 (1H, d), 9.44 (1H, s), 9.50 (2H, s).
Aufarbeitung
- stirringto stir at rt for 16 h
- filtrationfiltered
- washrinsing with EtOAc and MeOH
Quellen und Nachweise
- ORD-Eintrag
- ord-035f32fa89b9483b89b0cb389a5f49ed
- Quelldatensatz
- uspto-grants-2014_10
- Patentnummer
- US08859572B2
Notizen zur Reaktion
Wird geladen…